Myriad Genetics, Inc.
General ticker "MYGN" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $770.0M (TTM average)
Myriad Genetics, Inc. follows the US Stock Market performance with the rate: 5.4%.
Estimated limits based on current volatility of 3.7%: low 5.88$, high 6.33$
Factors to consider:
- Total employees count: 2700 (0.0%) as of 2024
- US accounted for 38.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Government payment risks, Regulatory and compliance, Litigation risks, Labor/talent shortage/retention
- Current price 14.2% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.92$, 17.25$]
- 2025-12-31 to 2026-12-31 estimated range: [6.90$, 14.86$]
Financial Metrics affecting the MYGN estimates:
- Positive: with PPE of 103.8 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -0.71 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of -0.84 <= -0.18
- Negative: 0.01 < Interest expense per share per price, % of 0.23
- Positive: -4.41 < Investing cash flow per share per price, % of -0.97
- Negative: Industry earnings per price (median), % of 0 <= 0
Short-term MYGN quotes
Long-term MYGN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $678.40MM | $753.20MM | $837.60MM |
| Operating Expenses | $819.00MM | $1,010.60MM | $961.10MM |
| Operating Income | $-140.60MM | $-257.40MM | $-123.50MM |
| Non-Operating Income | $0.00MM | $-4.80MM | $0.00MM |
| Interest Expense | $3.20MM | $2.90MM | $2.80MM |
| R&D Expense | $85.40MM | $88.70MM | $113.40MM |
| Income(Loss) | $-140.60MM | $-262.20MM | $-123.50MM |
| Taxes | $-28.60MM | $1.10MM | $3.80MM |
| Profit(Loss)* | $-112.00MM | $-263.30MM | $-127.30MM |
| Stockholders Equity | $885.80MM | $783.20MM | $701.10MM |
| Inventory | $20.10MM | $22.00MM | $27.50MM |
| Assets | $1,198.70MM | $1,146.50MM | $1,027.60MM |
| Operating Cash Flow | $-106.30MM | $-110.90MM | $-8.70MM |
| Capital expenditure | $45.30MM | $73.30MM | $29.70MM |
| Investing Cash Flow | $-77.50MM | $31.90MM | $-11.90MM |
| Financing Cash Flow | $-8.00MM | $152.90MM | $-7.40MM |
| Earnings Per Share** | $-1.39 | $-3.18 | $-1.41 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.